Clinical trials: Complete Response
Steroid-Refractory Acute Graft Versus Host Disease
A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002)
This is an open-label, randomized, Phase 3, multicenter trial, which has been designed to compare the efficacy and safety of T-Guard to ruxolitinib in patients with Grade III or IV Steroid-Refractory acute Graft-Versus-Host…
- Trial name
- 2002 (NCT04934670)
- Testing
- T-Guard, Ruxolitinib
- Where
- 48 sites in United States, Belgium and 7 more
- Volunteers
- 12 people
- Sponsor
- Xenikos
Chronic Phase Chronic Myeloid Leukemia
Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response
The study purpose is to test the hypothesis that Chronic Phase Chronic Myeloid Leukemia (CP-CML) patients with stable Complete Molecular Response (CMR) who discontinue Dasatinib treatment are able to maintain a sustained…
- Trial name
- DASFREE (NCT01850004)
- Testing
- Dasatinib
- Where
- 28 sites in United States, Canada and 4 more
- Volunteers
- 84 people
- Sponsor
- Bristol-Myers Squibb
Chronic Lymphocytic Leukemia (CLL)
A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent).
The purpose of this open-label, single-arm study was to evaluate the impact of venetoclax on the quality of life of participants including those with with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL; a type of…
- Trial name
- VENICE II (NCT02980731)
- Testing
- Venetoclax
- Where
- 33 sites in Argentina, Australia and 8 more
- Volunteers
- 210 people
- Sponsor
- AbbVie
Leukaemia, Myelocytic, Acute
Evaluation of a New Anti-cancer Immunotherapy After Chemotherapy in Adult Patients With Acute Myeloid Leukemia (AML)
This study is being done to evaluate the safety of a WT1 Antigen-Specific Cancer Immunotherapeutic (WT1 ASCI) as post-consolidation therapy in adult patients with WT1-positive Acute Myeloid Leukemia in first complete remission.
- Trial name
- NCT00725283
- Testing
- GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI)
- Where
- 10 sites in United States, France
- Volunteers
- 34 people
- Sponsor
- GlaxoSmithKline
Diffuse Large B-cell Lymphoma
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Phase III study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching placebo after patients had achieved complete response with first-line rituximab-chemotherapy
- Trial name
- PILLAR2 (NCT00790036)
- Testing
- Everolimus
- Where
- 202 sites in United States, Argentina and 32 more
- Volunteers
- 742 people
- Sponsor
- Novartis Pharmaceuticals
Parkinson's Disease
An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018
This is a 1-year, open-label, long-term safety extension for patients who have completed prior istradefylline studies 6002-EU-007, 6002-US-013 or 6002-US-018.
- Trial name
- NCT00199368
- Testing
- Istradefylline ( KW-6002)
- Where
- United States
- Volunteers
- 1,100 people
- Sponsor
- Kyowa Kirin, Inc.
Leukemia
Interleukin-2 Plus Histamine Dihydrochloride in Treating Patients With Acute Myeloid Leukemia
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill acute myeloid leukemia cells. Histamine dihydrochloride may prolong remission and reduce the risk of relapse in patients with acute myeloid leukemia in…
- Trial name
- NCT00003991
- Testing
- aldesleukin, histamine dihydrochloride
- Where
- 118 sites in United States, Australia and 10 more
- Volunteers
- 360 people
- Sponsor
- Maxim Pharmaceuticals
Ovarian Neoplasms
Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer
Comparison of Nexavar with a placebo as maintenance therapy for patients with advanced Ovarian or primary Peritoneal cancers in complete remission following surgery and one regimen of chemotherapy.
- Trial name
- NCT00791778
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- 59 sites in United States, Belgium and 12 more
- Volunteers
- 246 people
- Sponsor
- Bayer
Renal Cell Carcinoma
A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma.
Renal cell carcinoma (RCC) accounts for more than 200,000 new cases of cancer and over 100,000 cancer deaths annually in the World (Ferlay, et al., 2004).
- Trial name
- NCT01206764
- Testing
- RAD001
- Where
- 22 sites in Algeria, Egypt and 8 more
- Volunteers
- 143 people
- Sponsor
- Novartis Pharmaceuticals
Crohn's Disease
A Study of Vedolizumab in Adults With Crohn's Disease (CD)
The main aim of this study is to see if adults with CD treated with vedolizumab have less symptoms and inflammation of the bowel assessed by ultrasonography.
- Trial name
- SUNRISE (NCT05192863)
- Testing
- No Intervention
- Where
- 10 sites in Canada, Israel and 1 more
- Volunteers
- 72 people
- Sponsor
- Takeda
Gastroesophageal Reflux
Efficacy of Pantoprazole in Patients Older Than 18 Years Who Have Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/M3-339)
Gastroesophageal reflux disease (GERD) is a medical condition affecting the stomach and esophagus. GERD occurs when the lower esophageal sphincter does not close properly and stomach contents leaks back (refluxes) into the…
- Trial name
- NCT00163306
- Testing
- Pantoprazole
- Where
- 79 sites in Austria, Germany and 2 more
- Volunteers
- 1,200 people
- Sponsor
- Takeda
Hepatitis C, Chronic, Hepatitis C
Effect of Low-dose PegIntron on ALT Normalization in Japanese Patients With Chronic Hepatitis C (Study P04508)(COMPLETED)
In patients with chronic hepatitis C, the ultimate treatment goal is the improvement of liver histology and inhibition of progression to liver cirrhosis and hepatocellular carcinoma (HCC).
- Trial name
- NCT00787371
- Testing
- PegIntron (peginterferon alfa-2b)
- Volunteers
- 69 people
- Sponsor
- Merck Sharp & Dohme LLC
Leukemia, Myeloid, Acute
A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission
This is a first in human, prospective, multicenter, nonrandomized, open-label, dose-escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and immunogenicity of repeat doses of CSL362.
- Trial name
- NCT01632852
- Testing
- CSL362
- Where
- 5 sites in United States, Australia
- Volunteers
- 30 people
- Sponsor
- CSL Limited
Platinum Sensitive Relapsed Ovarian Cancer
Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations
Olaparib administered as monotherapy in the maintenance setting improves progression free survival compared to placebo in patients whose tumours carry loss of function (deleterious or suspected deleterious) somatic BRCA mutations…
- Trial name
- NCT02392676
- Testing
- OLAPARIB
- Where
- 29 sites in United States, Peru and 3 more
- Sponsor
- AstraZeneca
Ovarian Neoplasms
A Trial to Evaluate the Safety of Niraparib Tablets in Adult Female Participants With Advanced or Relapsed Epithelial Ovarian Cancer
The goal of this clinical trial is to learn about the safety profile of niraparib in adult female participants for the treatment of advanced or relapsed epithelial ovarian cancer.
- Trial name
- NCT06887933
- Testing
- Niraparib
- Volunteers
- 67 people
- Sponsor
- GlaxoSmithKline
GERD
Pantoprazole Magnesium 40 mg Versus Esomeprazole 40 mg in Patients With Erosive Gastroesophageal Reflux Disease
The aim of this trial is to evaluate the complete remission of erosive gastroesophageal reflux disease with pantoprazole magnesium 40 mg once daily versus esomeprazole 40 mg once daily during four-week treatment with an extension…
- Trial name
- PAMES 0109 (NCT01132638)
- Testing
- Magnesium Pantoprazole, Magnesium Esomeprazole
- Where
- 9 sites in Brazil
- Volunteers
- 713 people
- Sponsor
- Takeda
B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
Historical Data Analysis of Complete Remission in Children With R/R Acute Lymphoblastic Leukemia (ALL)
An historical data comparator study for children with relapsed/refactory acute lymphoblastic leukemia (ALL).
- Trial name
- NCT02303522
- Testing
- Other: not applicable - observational study
- Where
- 3 sites in Austria, Germany and 1 more
- Volunteers
- 207 people
- Sponsor
- Amgen
Hepatitis C, Chronic
PEG-IFN Alfa-2b Plus Ribavirin for Treatment of Mexican naïve Patients With Chronic Hepatitis C Infected With Genotype 1 (Study P04511)(COMPLETED)
This study aims to evaluate the efficacy and safety of peginterferon alfa-2b plus weight-based ribavirin as initial treatment in chronic hepatitis C virus (HCV) genotype 1 patients.
- Trial name
- NCT00724620
- Testing
- Peginterferon alfa-2b (SCH 054031), Ribavirin (SCH 018908)
- Volunteers
- 103 people
- Sponsor
- Schering-Plough
Acute Myeloid Leukemia, Leukemia
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
This clinical two-arm trial is designed to evaluate two doses of quizartinib as maintenance therapy after induction/consolidation in participants with FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) (+) acute…
- Trial name
- NCT06824168
- Testing
- Quizartinib High Dose, Quizartinib Low Dose
- Where
- 64 sites in United States, Australia and 3 more
- Volunteers
- 130 people
- Sponsor
- Daiichi Sankyo
General Population (no Specific Condition or Disease)
Evaluation of Reminder Strategies (Emails and Text Messages) to Increase Participation in the Le French Gut E-cohort
This study is a randomized controlled trial nested in the "Le French Gut" e-cohort aiming to test the efficacy of 4 reminder strategies (emails and/or SMS with standard and/or institutional wording) in increasing participation of…
- Trial name
- NCT07473466
- Testing
- 3 standard email reminders, 3 institutional email reminders, 3 SMS reminders
- Where
- France
- Volunteers
- 20,487 people, healthy volunteers welcome
- Sponsor
- SKEZI